Personal Information
Organization / Workplace
North Miami, Florida United States
Industry
Medical / Health Care / Pharmaceuticals
Website
www.imeronline.com
About
The mission of IMER is to enhance the knowledge, skills, and performance of health care professionals to ensure that patients receive the highest quality of care possible, resulting in improved patient outcomes. We engage health care professionals in fair-balanced, scientifically rigorous, expert-led accredited educational programs designed to foster professional development.
Tags
oncology
melanoma
md
cancer
ipilimumab
cml
metastatic
breast cancer
immuno-oncology
phd
endocrinopathies
chronic myelogenous leukemia
braf inhibitor
imatinib
prostate cancer
bevacizumab
docetaxel
ovarian
ovarian cancer
immune-related adverse events.
vaccines
immunotherapies
non-small cell lung cancer
anti-ctla-4
renal cell carcinoma
her2 positive
anthracyclines
hormonal therapy
her2+
her2-targeted therapy
endocrine therapy
adjuvant therapy
receptor
targeted therapy
positive
aromatase inhibitors
advanced
pi3k/mtor inhibitors
combination therapy
estrogen
endocrine-resistance
vegf pathway
antiangiogenic agents
antiangiogenesis
pdgf
therapies
fgf
vegf
antiangiogenic
iraes
imer
gi
dacarbazine
mek inhibitors
braf
ctla4 inhibitors
antoni ribas md
cancer care
john powderly ii
androgen-ablation
charles g. drake
imiquimod
cd8+ cytotoxic t lymphocyte
prostate
ctla-4
tlr ligands
tumor antigens
tremelimumab
thomas f. gajewski
jorge e. cortes
jerald p. radich
michael wn deininger
evan m. hersh md
mapk pathway
hypophysitis
kaplan-meier analysis
peg esper
mdx010-20
krista m. rubin
vemurafenib
sokal
hasford scoresdasatinib ipilimumab
tyrosine kinase inhibitors
tkis
dasatinib
nilotinib
kathleen k. curran
mollie e. moran
michael r. savona
philadelphia chromosome
anti-ctla4 antibody
perifosine/bortezomib
lenalidomide
venous thromboembolic events
gcsf
bortezomib
vte
calgb 100104 schema
maintenance therapy
cyclophosphamide
pat killingsworth
crab
page bertolotti
sundar jagannath
beth faiman
hypogammaglobulinemia
multiple myeloma
so325 trial design
iris study
fish
cytogenetic response
tops trial
mutational analysis
chronic
michael w. n. deininger
leukemia
myelogenous
bcr-abl
hpv status
anti-angiogenic agents
egfr inhibitors
hnc
marshall r. posner
head and neck
dexamethasone
emmanuel antonarakis
abiraterone
dr. a. oliver sartor
cabazitaxel
leonard gomella
immunotherapy
sipuleucel-t
prospect trial
tropic trial
diphenhydramine
ketoconazole
tax 327
crpc
cabazitaxel-prednisone
swog 9916
castration-resistant
maurie markman md
cisplatin
carboplatin
vismodegib
hedgehog inhibitor
basal cell carcinoma
jean y. tang
bcc
See more
Presentations
(16)Personal Information
Organization / Workplace
North Miami, Florida United States
Industry
Medical / Health Care / Pharmaceuticals
Website
www.imeronline.com
About
The mission of IMER is to enhance the knowledge, skills, and performance of health care professionals to ensure that patients receive the highest quality of care possible, resulting in improved patient outcomes. We engage health care professionals in fair-balanced, scientifically rigorous, expert-led accredited educational programs designed to foster professional development.
Tags
oncology
melanoma
md
cancer
ipilimumab
cml
metastatic
breast cancer
immuno-oncology
phd
endocrinopathies
chronic myelogenous leukemia
braf inhibitor
imatinib
prostate cancer
bevacizumab
docetaxel
ovarian
ovarian cancer
immune-related adverse events.
vaccines
immunotherapies
non-small cell lung cancer
anti-ctla-4
renal cell carcinoma
her2 positive
anthracyclines
hormonal therapy
her2+
her2-targeted therapy
endocrine therapy
adjuvant therapy
receptor
targeted therapy
positive
aromatase inhibitors
advanced
pi3k/mtor inhibitors
combination therapy
estrogen
endocrine-resistance
vegf pathway
antiangiogenic agents
antiangiogenesis
pdgf
therapies
fgf
vegf
antiangiogenic
iraes
imer
gi
dacarbazine
mek inhibitors
braf
ctla4 inhibitors
antoni ribas md
cancer care
john powderly ii
androgen-ablation
charles g. drake
imiquimod
cd8+ cytotoxic t lymphocyte
prostate
ctla-4
tlr ligands
tumor antigens
tremelimumab
thomas f. gajewski
jorge e. cortes
jerald p. radich
michael wn deininger
evan m. hersh md
mapk pathway
hypophysitis
kaplan-meier analysis
peg esper
mdx010-20
krista m. rubin
vemurafenib
sokal
hasford scoresdasatinib ipilimumab
tyrosine kinase inhibitors
tkis
dasatinib
nilotinib
kathleen k. curran
mollie e. moran
michael r. savona
philadelphia chromosome
anti-ctla4 antibody
perifosine/bortezomib
lenalidomide
venous thromboembolic events
gcsf
bortezomib
vte
calgb 100104 schema
maintenance therapy
cyclophosphamide
pat killingsworth
crab
page bertolotti
sundar jagannath
beth faiman
hypogammaglobulinemia
multiple myeloma
so325 trial design
iris study
fish
cytogenetic response
tops trial
mutational analysis
chronic
michael w. n. deininger
leukemia
myelogenous
bcr-abl
hpv status
anti-angiogenic agents
egfr inhibitors
hnc
marshall r. posner
head and neck
dexamethasone
emmanuel antonarakis
abiraterone
dr. a. oliver sartor
cabazitaxel
leonard gomella
immunotherapy
sipuleucel-t
prospect trial
tropic trial
diphenhydramine
ketoconazole
tax 327
crpc
cabazitaxel-prednisone
swog 9916
castration-resistant
maurie markman md
cisplatin
carboplatin
vismodegib
hedgehog inhibitor
basal cell carcinoma
jean y. tang
bcc
See more